ArticleEuropean journal of nuclear medicine and molecular imaging2014
¹⁸F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study.
Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- The dilemma ofEndocrine · 2021Pooled it
- [Molecular imaging and biology · 2023Trial
- Papillary Thyroid Microcarcinomas Detected by Nuclear Medicine Imaging: Distinct Clinicopathological Features Compared with Conventional Modalities.Molecular imaging and radionuclide therapy · 2026Article
- Putative mitochondrial components of frontotemporal lobar degeneration: topological correlations between mitochondrial density and atrophy in FTLD/FTD phenotypes.Journal of neurology · 2025Article
- Visual and QuantitativeMolecular imaging and biology · 2025Article
- Enhanced staging of differentiated thyroid carcinoma: integrating [European journal of nuclear medicine and molecular imaging · 2025Article
- New developments in imaging in ALS.Journal of neurology · 2025Review
- Prognostic value of TLR from FDG PET/CT in patients with margin-negative stage IB and IIA non-small cell lung cancer.European radiology · 2023Article
- Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer.Molecules (Basel, Switzerland) · 2022Review
- Indeterminate thyroid nodules. The role ofEndocrine · 2020Article
- Review
- EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy.European journal of nuclear medicine and molecular imaging · 2019Article
- Evaluation of Malignancy Risk in 18F-FDG PET/CT Thyroid Incidentalomas.Diagnostics (Basel, Switzerland) · 2019Article
- Prognostic value ofEuropean journal of nuclear medicine and molecular imaging · 2019Article
- PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art.Reviews in endocrine & metabolic disorders · 2019Review
- Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.European journal of nuclear medicine and molecular imaging · 2017Article
- Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications.Journal of endocrinological investigation · 2017Article
- Analysis of predictability of F-18 fluorodeoxyglucose-PET/CT in the recurrence of papillary thyroid carcinoma.Cancer medicine · 2016Article
- Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2016Article
- Employing Bayesian approach to the intermediate risk categories of the Bethesda thyroid cytopathology reporting system: can FDG PET/CT find a strong enough evidence-base to be practised clinically as an adjunct?European journal of nuclear medicine and molecular imaging · 2014Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOur aim was to investigate the association between (18)F-fluorodeoxyglucose (FDG) uptake and event-free survival in patients in whom a differentiated thyroid cancer (DTC) was detected by (18)F-FDG positron emission tomography (PET)/CT.
methodsAmong 884 focal (18)F-FDG PET thyroid incidentalomas referred to our 4 Nuclear Medicine Departments, we investigated 54 patients in whom a DTC was confirmed and a clinical follow-up was available. The ratio between maximum standardized uptake value (SUVmax) of DTC and SUVmean of the liver (SUV ratio) was recorded for each scan. All patients underwent total thyroidectomy and (131)I remnant ablation. After a median follow-up of 39 months we assessed the outcome. The association between disease persistence/progression, (18)F-FDG uptake and other risk factors (T, N, M and histological subtype) was evaluated through univariate and multivariate analyses.
resultsOf the 54 patients, 39 achieved complete remission. The remaining 15 showed persistence/progression of disease. High (18)F-FDG uptake, i.e. SUV ratio ≥3, showed a low positive predictive value (48 %). Low (18)F-FDG uptake (SUV ratio < 3) displayed a high negative predictive value (93 %). The median of SUV ratios in T1-T2 (2.2), in M0 (2.7) and in non-virulent subtypes (2.7) were significantly lower (p < 0.03) than in T3-T4 (5.0), M1 (7.3) and virulent subtypes (6.0). Kaplan-Maier analysis showed a significant association between high (18)F-FDG uptake and disease persistence/progression (p = 0.001). When we adjusted risk estimates by using a multivariate Cox model, only T (p = 0.05) remained independently associated with disease persistence/progression.
conclusionAn intense (18)F-FDG uptake of the primary DTC is associated with persistence/progression of disease. However, when all other prognostic factors have been taken into account, (18)F-FDG uptake does not add further prognostic information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.